Literature DB >> 23370352

Activation of c-Jun N-terminal kinase mediates tanshinone IIA-induced apoptosis in KBM-5 chronic myeloid leukemia cells.

Sun-Mi Yun1, Soo-Jin Jeong, Ji-Hyun Kim, Ji Hoon Jung, Hyo-Jung Lee, Eun Jung Sohn, Min-Ho Lee, Sung-Hoon Kim.   

Abstract

Aim of this study was to identify the molecular mechanisms of tanshinone IIA-induced apoptosis in chronic myelogenous leukemia (CML) cells. Cytotoxicity of tanshinone IIA was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Our data demonstrate that tanshinone IIA induced apoptosis by increasing the sub-G1 DNA contents and DNA fragmentation in KBM-5 CML cell line. In addition, tanshinone IIA significantly reduced mitochondrial membrane potential (MMP), mediated cytochrome c release from mitochondria and activated caspase-3 and 9, indicating mitochondria-dependent apoptosis by tanshinone IIA. Tanshinone IIA attenuated expression of several apoptosis-related proteins such as c-inhibitor of apoptosis protein (IAP) 2, Mcl-1(L) and Bcl-2. Interestingly, although tanshinone IIA notably enhanced the phosphorylation of both c-Jun N-terminal protein kinase (JNK) and p38, JNK inhibitor, but not p38 inhibitor, reversed tanshinone IIA-induced apoptosis. Our findings suggest that tanshinone IIA induces mitochondria-dependent apoptosis via activation of JNK in KBM 5 cells as a potent anti-cancer agent for CML therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23370352     DOI: 10.1248/bpb.b12-00537

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  6 in total

1.  Inhibition of the spinal astrocytic JNK/MCP-1 pathway activation correlates with the analgesic effects of tanshinone IIA sulfonate in neuropathic pain.

Authors:  Jun Tang; Chao Zhu; Zhi-hong Li; Xiao-yu Liu; Shu-kai Sun; Ting Zhang; Zhuo-jing Luo; Hui Zhang; Wei-yan Li
Journal:  J Neuroinflammation       Date:  2015-03-25       Impact factor: 8.322

2.  The anticancer mechanism investigation of Tanshinone IIA by pharmacological clustering in protein network.

Authors:  Yan-Feng Cao; Shi-Feng Wang; Xi Li; Yan-Ling Zhang; Yan-Jiang Qiao
Journal:  BMC Syst Biol       Date:  2018-10-29

3.  Farnesiferol C Induces Apoptosis in Chronic Myelogenous Leukemia Cells as an Imatinib Sensitizer via Caspase Activation and HDAC (Histone Deacetylase) Inactivation.

Authors:  Ji Hoon Jung; Ji Eon Park; Deok Yong Sim; Eunji Im; Woon Yi Park; Duckgue Lee; Bum-Sang Shim; Sung-Hoon Kim
Journal:  Int J Mol Sci       Date:  2019-11-06       Impact factor: 5.923

4.  Tanshinone I inhibited growth of human chronic myeloid leukemia cells via JNK/ERK mediated apoptotic pathways.

Authors:  Siya Sun; Lingyan Zhu; Mengru Lai; Rubin Cheng; Yuqing Ge
Journal:  Braz J Med Biol Res       Date:  2021-05-24       Impact factor: 2.590

5.  Apoptosis Induced by Tanshinone IIA and Cryptotanshinone Is Mediated by Distinct JAK/STAT3/5 and SHP1/2 Signaling in Chronic Myeloid Leukemia K562 Cells.

Authors:  Ji Hoon Jung; Tae-Rin Kwon; Soo-Jin Jeong; Eun-Ok Kim; Eun Jung Sohn; Miyong Yun; Sung-Hoon Kim
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-26       Impact factor: 2.629

6.  Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB‑152 in vivo and in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway.

Authors:  Zhi Teng; Shijuan Xu; Qin Lei
Journal:  Oncol Rep       Date:  2019-12-31       Impact factor: 3.906

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.